Functional role of miR-10b in tamoxifen resistance of ER-positive breast cancer cells through down-regulation of HDAC4

BMC Cancer

Volumn 15, Issue 1, 2015, Pages

  Ahmad, Aamir ^a   Ginnebaugh, Kevin R ^a   Yin, Shuping ^a   Bollig Fischer, Aliccia ^a   Reddy, Kaladhar B ^a   Sarkar, Fazlul H ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

ER positive breast cancers; HDAC4; miR 10b; Tamoxifen resistance

Indexed keywords

HERMES ANTIGEN; HISTONE DEACETYLASE 4; KRUPPEL LIKE FACTOR 4; MICRORNA; MICRORNA 10B; POLYCYSTIN 1; SMALL INTERFERING RNA; TAMOXIFEN; TETRAZOLIUM; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR HOXA1; TRANSCRIPTION FACTOR HOXA10; TRANSCRIPTION FACTOR HOXD10; TRANSCRIPTION FACTOR TWIST; UNCLASSIFIED DRUG; 3' UNTRANSLATED REGION; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; ESTROGEN RECEPTOR; HDAC4 PROTEIN, HUMAN; HISTONE DEACETYLASE; MIRN10 MICRORNA, HUMAN; REPRESSOR PROTEIN;

3' UNTRANSLATED REGION; APOPTOSIS; ARTICLE; BREAST CANCER; BREAST CANCER CELL LINE; CANCER INHIBITION; CANCER PATIENT; CELL DEATH; CELL INVASION; CELL MIGRATION; CELL VIABILITY; CONTROLLED STUDY; DOWN REGULATION; ENZYME LINKED IMMUNOSORBENT ASSAY; EPITHELIAL MESENCHYMAL TRANSITION; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; HUMAN; HUMAN CELL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; REAL TIME POLYMERASE CHAIN REACTION; WESTERN BLOTTING; BREAST NEOPLASMS; DRUG RESISTANCE; FEMALE; GENETICS; MCF-7 CELL LINE; METABOLISM; TUMOR CELL LINE;

3' UNTRANSLATED REGIONS; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CELL LINE, TUMOR; DOWN-REGULATION; DRUG RESISTANCE, NEOPLASM; FEMALE; HISTONE DEACETYLASES; HUMANS; MCF-7 CELLS; MICRORNAS; RECEPTORS, ESTROGEN; REPRESSOR PROTEINS; TAMOXIFEN;

EID: 85019172149     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/s12885-015-1561-x     Document Type: Article

References (49)

1. Osborne CK, Schiff R. Mechanisms of endocrine resistance in breast cancer. Annu Rev Med. 2011;62:233-47.
2. Musgrove EA, Sutherland RL. Biological determinants of endocrine resistance in breast cancer. Nat Rev Cancer. 2009;9(9):631-43.
3. Ramaswamy B, Lu YZ, Teng KY, Nuovo G, Li XB, Shapiro CL, et al. Hedgehog signaling is a novel therapeutic target in tamoxifen resistant breast cancer aberrantly activated by PI3K/AKT pathway. Cancer Res. 2012;72(19):5048-59.
4. Sarkar FH, Li Y, Wang Z, Kong D, Ali S. Implication of microRNAs in drug resistance for designing novel cancer therapy. Drug Resist Updat. 2010;13(3):57-66.
5. Zhao JJ, Lin J, Yang H, Kong W, He L, Ma X, et al. MicroRNA-221/222 negatively regulates estrogen receptor alpha and is associated with tamoxifen resistance in breast cancer. J Biol Chem. 2008;283(45):31079-86.
6. Miller TE, Ghoshal K, Ramaswamy B, Roy S, Datta J, Shapiro CL, et al. MicroRNA-221/222 confers tamoxifen resistance in breast cancer by targeting p27Kip1. J Biol Chem. 2008;283(44):29897-903.
7. Cittelly DM, Das PM, Salvo VA, Fonseca JP, Burow ME, Jones FE. Oncogenic HER2{Delta}16 suppresses miR-15a/16 and deregulates BCL-2 to promote endocrine resistance of breast tumors. Carcinogenesis. 2010;31(12):2049-57.
8. Cittelly DM, Das PM, Spoelstra NS, Edgerton SM, Richer JK, Thor AD, et al. Downregulation of miR-342 is associated with tamoxifen resistant breast tumors. Mol Cancer. 2010;9:317.
9. Ward A, Balwierz A, Zhang JD, Kublbeck M, Pawitan Y, Hielscher T, et al. Re-expression of microRNA-375 reverses both tamoxifen resistance and accompanying EMT-like properties in breast cancer. Oncogene. 2012;32(9):1173-82.
10. Manavalan TT, Teng Y, Litchfield LM, Muluhngwi P, Al-Rayyan N, Klinge CM. Reduced expression of miR-200 family members contributes to antiestrogen resistance in LY2 human breast cancer cells. PLoS One. 2013;8(4):e62334.
11. Hoppe R, Achinger-Kawecka J, Winter S, Fritz P, Lo WY, Schroth W, et al. Increased expression of miR-126 and miR-10a predict prolonged relapse-free time of primary oestrogen receptor-positive breast cancer following tamoxifen treatment. Eur J Cancer. 2013;49(17):3598-608.
12. Ward A, Shukla K, Balwierz A, Soons Z, Konig R, Sahin O, et al. MicroRNA-519a is a novel oncomir conferring tamoxifen resistance by targeting a network of tumour-suppressor genes in ER+ breast cancer. J Pathol. 2014;233(4):368-79. doi: 10.1002/path.4363 .
13. Ahmad A, Aboukameel A, Kong D, Wang Z, Sethi S, Chen W, et al. Phosphoglucose isomerase/autocrine motility factor mediates epithelial-mesenchymal transition regulated by miR-200 in breast cancer cells. Cancer Res. 2011;71(9):3400-9.
14. Ahmad A, Ali AS, Ali S, Wang Z, Kong D, Sarkar FH. MicroRNAs: targets of interest in breast cancer research. In: Mulligan JA, editor. MicroRNA: expression, detection and therapeutic strategies. New York: Nova Publishers; 2011. p. 59-78.
15. Zhao Y, Deng C, Lu W, Xiao J, Ma D, Guo M, et al. let-7 microRNAs induce tamoxifen sensitivity by downregulation of estrogen receptor alpha signaling in breast cancer. Mol Med (Cambridge, Mass). 2011;17(11-12):1233-41. doi: 10.2119/molmed.2010.00225 .
16. Foroni C, Broggini M, Generali D, Damia G. Epithelial-mesenchymal transition and breast cancer: role, molecular mechanisms and clinical impact. Cancer Treat Rev. 2012;38(6):689-97.
17. Ma L, Teruya-Feldstein J, Weinberg RA. Tumour invasion and metastasis initiated by microRNA-10b in breast cancer. Nature. 2007;449(7163):682-8.
18. Gyorffy B, Lanczky A, Eklund AC, Denkert C, Budczies J, Li Q, et al. An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients. Breast Cancer Res Treat. 2010;123(3):725-31. doi: 10.1007/s10549-009-0674-9 .
19. Leong H, Sloan JR, Nash PD, Greene GL. Recruitment of histone deacetylase 4 to the N-terminal region of estrogen receptor alpha. Mol Endocrinol (Baltimore, Md). 2005;19(12):2930-42. doi: 10.1210/me.2005-0178 .
20. Dai Y, Huang L. Understanding tamoxifen resistance of breast cancer based on integrative bioinformatics approaches. In: Ahmad A, editor. Breast cancer metastasis and drug resistance. New York: Springer; 2013. p. 249-60.
21. Kim MR, Choi HK, Cho KB, Kim HS, Kang KW. Involvement of Pin1 induction in epithelial-mesenchymal transition of tamoxifen-resistant breast cancer cells. Cancer Sci. 2009;100(10):1834-41. doi: 10.1111/j.1349-7006.2009.01260.x .
22. Shah KN, Mehta KR, Peterson D, Evangelista M, Livesey JC, Faridi JS. AKT-induced tamoxifen resistance is overturned by RRM2 inhibition. Mol Cancer Res: MCR. 2014;12(3):394-407. doi: 10.1158/1541-7786.mcr-13-0219 .
23. Lombardo Y, Faronato M, Filipovic A, Vircillo V, Magnani L, Coombes RC. Nicastrin and Notch4 drive endocrine therapy resistance and epithelial to mesenchymal transition in MCF7 breast cancer cells. Breast Cancer Res: BCR. 2014;16(3):R62. doi: 10.1186/bcr3675 .
24. Bergamaschi A, Madak-Erdogan Z, Kim Y, Choi YL, Lu H, Katzenellenbogen BS. The forkhead transcription factor FOXM1 promotes endocrine resistance and invasiveness in estrogen receptor-positive breast cancer by expansion of stem-like cancer cells. Breast Cancer Res: BCR. 2014;16(5):436. doi: 10.1186/s13058-014-0436-4 .
25. Palena C, Roselli M, Litzinger MT, Ferroni P, Costarelli L, Spila A, et al. Overexpression of the EMT driver brachyury in breast carcinomas: association with poor prognosis. J Natl Cancer Inst. 2014;106(5). doi: 10.1093/jnci/dju054 .
26. Dubrovska A, Hartung A, Bouchez LC, Walker JR, Reddy VA, Cho CY, et al. CXCR4 activation maintains a stem cell population in tamoxifen-resistant breast cancer cells through AhR signalling. Br J Cancer. 2012;107(1):43-52. doi: 10.1038/bjc.2012.105 .
27. Wang X, Wang G, Zhao Y, Liu X, Ding Q, Shi J, et al. STAT3 mediates resistance of CD44(+)CD24(-/low) breast cancer stem cells to tamoxifen in vitro. J Biomed Res. 2012;26(5):325-35. doi: 10.7555/jbr.26.20110050 .
28. Piva M, Domenici G, Iriondo O, Rabano M, Simoes BM, Comaills V, et al. Sox2 promotes tamoxifen resistance in breast cancer cells. EMBO Mol Med. 2014;6(1):66-79. doi: 10.1002/emmm.201303411 .
29. Reijm EA, Timmermans AM, Look MP, Meijer-van Gelder ME, Stobbe CK, van Deurzen CH, et al. High protein expression of EZH2 is related to unfavorable outcome to tamoxifen in metastatic breast cancer. Ann Oncol: Off J Eur Soc Med Oncol / ESMO. 2014;25(11):2185-90. doi: 10.1093/annonc/mdu391 .
30. Yenigun VB, Ozpolat B, Kose GT. Response of CD44+/CD24-/low breast cancer stem/progenitor cells to tamoxifen and doxorubicininduced autophagy. Int J Mol Med. 2013;31(6):1477-83. doi: 10.3892/ijmm.2013.1342 .
31. Raffo D, Berardi DE, Pontiggia O, Todaro L, de Kier Joffe EB, Simian M. Tamoxifen selects for breast cancer cells with mammosphere forming capacity and increased growth rate. Breast Cancer Res Treat. 2013;142(3):537-48. doi: 10.1007/s10549-013-2760-2 .
32. Ibrahim SA, Yip GW, Stock C, Pan JW, Neubauer C, Poeter M, et al. Targeting of syndecan-1 by microRNA miR-10b promotes breast cancer cell motility and invasiveness via a Rho-GTPase- and E-cadherin-dependent mechanism. Int J Cancer. 2012;131(6):E884-96. doi: 10.1002/ijc.27629 .
33. Han X, Yan S, Weijie Z, Feng W, Liuxing W, Mengquan L, et al. Critical role of miR-10b in transforming growth factor-beta1-induced epithelial-mesenchymal transition in breast cancer. Cancer Gene Ther. 2014;21(2):60-7. doi: 10.1038/cgt.2013.82 .
34. Guessous F, Alvarado-Velez M, Marcinkiewicz L, Zhang Y, Kim J, Heister S, et al. Oncogenic effects of miR-10b in glioblastoma stem cells. J Neuro-Oncol. 2013;112(2):153-63. doi: 10.1007/s11060-013-1047-0 .
35. Port M, Glaesener S, Ruf C, Riecke A, Bokemeyer C, Meineke V, et al. Micro-RNA expression in cisplatin resistant germ cell tumor cell lines. Mol Cancer. 2011;10:52.
36. Nishida N, Yamashita S, Mimori K, Sudo T, Tanaka F, Shibata K, et al. MicroRNA-10b is a prognostic indicator in colorectal cancer and confers resistance to the chemotherapeutic agent 5-fluorouracil in colorectal cancer cells. Ann Surg Oncol. 2012;19(9):3065-71.
37. Gan R, Yang Y, Yang X, Zhao L, Lu J, Meng QH. Downregulation of miR-221/222 enhances sensitivity of breast cancer cells to tamoxifen through upregulation of TIMP3. Cancer Gene Ther. 2014;21(7):290-6. doi: 10.1038/cgt.2014.29 .
38. Wei Y, Lai X, Yu S, Chen S, Ma Y, Zhang Y, et al. Exosomal miR-221/222 enhances tamoxifen resistance in recipient ER-positive breast cancer cells. Breast Cancer Res Treat. 2014;147(2):423-31. doi: 10.1007/s10549-014-3037-0 .
39. Bergamaschi A, Katzenellenbogen BS. Tamoxifen downregulation of miR-451 increases 14-3-3zeta and promotes breast cancer cell survival and endocrine resistance. Oncogene. 2012;31(1):39-47. doi: 10.1038/onc.2011.223 .
40. Giaginis C, Alexandrou P, Delladetsima I, Giannopoulou I, Patsouris E, Theocharis S. Clinical significance of histone deacetylase (HDAC)-1, HDAC-2, HDAC-4, and HDAC-6 expression in human malignant and benign thyroid lesions. Tumour Biol: J Int Soc Oncodev Biol Med. 2014;35(1):61-71. doi: 10.1007/s13277-013-1007-5 .
41. Kang ZH, Wang CY, Zhang WL, Zhang JT, Yuan CH, Zhao PW, et al. Histone deacetylase HDAC4 promotes gastric cancer SGC-7901 cells progression via p21 repression. PLoS One. 2014;9(6):e98894. doi: 10.1371/journal.pone.0098894 .
42. Niegisch G, Knievel J, Koch A, Hader C, Fischer U, Albers P, et al. Changes in histone deacetylase (HDAC) expression patterns and activity of HDAC inhibitors in urothelial cancers. Urol Oncol. 2013;31(8):1770-9. doi: 10.1016/j.urolonc.2012.06.015 .
43. Stronach EA, Alfraidi A, Rama N, Datler C, Studd JB, Agarwal R, et al. HDAC4-regulated STAT1 activation mediates platinum resistance in ovarian cancer. Cancer Res. 2011;71(13):4412-22. doi: 10.1158/0008-5472.can-10-4111 .
44. Kaewpiboon C, Srisuttee R, Malilas W, Moon J, Oh S, Jeong HG, et al. Upregulation of Stat1-HDAC4 confers resistance to etoposide through enhanced multidrug resistance 1 expression in human A549 lung cancer cells. Mol Med Rep. 2015;11(3):2315-21. doi: 10.3892/mmr.2014.2949 .
45. Yu SL, Lee DC, Son JW, Park CG, Lee HY, Kang J. Histone deacetylase 4 mediates SMAD family member 4 deacetylation and induces 5-fluorouracil resistance in breast cancer cells. Oncol Rep. 2013;30(3):1293-300. doi: 10.3892/or.2013.2578 .
46. Colarossi L, Memeo L, Colarossi C, Aiello E, Iuppa A, Espina V, et al. Inhibition of histone deacetylase 4 increases cytotoxicity of docetaxel in gastric cancer cells. Proteomics Clin Appl. 2014;8(11-12):924-31. doi: 10.1002/prca.201400058 .
47. Song B, Wang Y, Xi Y, Kudo K, Bruheim S, Botchkina GI, et al. Mechanism of chemoresistance mediated by miR-140 in human osteosarcoma and colon cancer cells. Oncogene. 2009;28(46):4065-74. doi: 10.1038/onc.2009.274 .
48. Kong D, Ahmad A, Bao B, Li Y, Banerjee S, Sarkar FH. Histone deacetylase inhibitors induce epithelial-to-mesenchymal transition in prostate cancer cells. PLoS One. 2012;7(9):e45045. doi: 10.1371/journal.pone.0045045 .
49. Waddell N, Cocciardi S, Johnson J, Healey S, Marsh A, Riley J, et al. Gene expression profiling of formalin-fixed, paraffin-embedded familial breast tumours using the whole genome-DASL assay. J Pathol. 2010;221(4):452-61. doi: 10.1002/path.2728 .